care delivery.
While needle anxiety is often linked to pediatric care, it’ s a widespread issue among adults as well, creating a much larger opportunity across therapeutic areas. For instance, we recently piloted the use of N-FIS in gynecology and successfully launched it in the department earlier this month. This reinforces the platform’ s adaptability across multiple clinical use cases.
The global market for needle-free injectors is projected to grow substantially, reaching an estimated value of $ 27.65 billion by 2028
Looking ahead, we are expanding our efforts into areas such as IVF treatments, growth hormone therapy, and pain management, where patient-centric, needle-free delivery can significantly improve both clinical outcomes and patient experience.
What growth opportunities are you most excited about over the next 3 – 5 years?
Over the next three to five years, IntegriMedical is focused on scaling both its technology and geographic reach. The company is actively pursuing regulatory approvals in additional international markets, i. e, Europe, South America, the Middle East, and Canada, to drive global adoption of the N-FIS device. Domestically, it is prioritizing deeper penetration across India, particularly in Tier-2 and Tier-3 cities, to ensure broader accessibility.
Strategic partnerships with pharmaceutical companies are in progress to enable co-packaging of N-FIS with vaccines and other medications, making delivery more convenient and encouraging widespread clinical integration. Beyond pediatrics, we’ re expanding into new therapeutic areas such as gynecology, infertility care, diabetes management, and IVF, where reducing patient discomfort can significantly improve treatment adherence and experience. With sustained investment in R & D, the company aims to enhance the device’ s functionality and versatility. Collaborations with healthcare agencies, NGOs, and government programs will further help position needle-free injections as a mainstream, patient-friendly alternative, advancing public health goals at scale.
heathtech
BIOVOICENEWS. COM 47